UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 3, 2007
NEOGEN CORPORATION
(Exact name of registrant as specified in its charter)
| MICHIGAN | 0-17988 | 38-2367843 | ||
| (State or other jurisdiction Of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 620 Lesher Place Lansing, Michigan | 48912 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 517-372-9200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.01. | Completion of Acquisition or Disposition of Assets |
On December 4, 2007 Neogen Corporation (Neogen) issued a press release announcing that on December 3, 2007 it had acquired the assets of Winnipeg Manitoba Canada based Rivard Instruments, Inc. (Rivard). Assets acquired consisted of inventory, equipment and intangibles. Neogen expects to relocate the business to Lexington Kentucky and integrate it with its Animal Safety division. There was no prior relationship between Neogen and Rivard although the companies had been involved in patent litigation in the United States and Canada. The acquisition provides for settlement of the litigation.
The amount of consideration was not disclosed. The source of the consideration was Neogen Corporation cash balances. Based on the level of future sales of detectable needles, additional contingent consideration could be paid.
A copy of the press release is attached as Exhibit 99.1 to this report.
| ITEM 9.01. | Financial Statement and Exhibits |
(a) Financial statements and pro forma financial statements of the businesses acquired are inapplicable and, therefore, have been omitted.
(b) Exhibit 99.1—Press Release dated December 4, 2007 announcing Neogen Corporation’s acquisition of the Assets of Rivard Industries, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEOGEN CORPORATION | ||||
| (Registrant) | ||||
| Date: December 4, 2007 | ||||
| /s/ Richard R. Current | ||||
| Richard R. Current | ||||
| Vice President & CFO |